EUVIMEDEUVIMED entdecken
Crossref

Serum autoantibody signatures enable non-invasive early detection of pancreatic cancer

Li Sun, Yuqi Liu, Qian Yang, Jicun Zhu, Tiandong Li, Donglin Jiang, Yin Lu, Ling Liu, Yue Wang, Xiaodan Zhang, Zihan Wang, Hanke Ma und 6 weitere

Pancreatology · 2026

DOI: 10.1016/j.pan.2025.11.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pancreatology, 2026. Verfasst von Li Sun und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Autoantibodies, Early Detection of Cancer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Zhengzhou University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Autoantibodies against tumor-associated antigens (TAAs) are promising biomarkers for early immunodiagnosis of cancers. This study was designed to screen and verify tumor-associated autoantibodies (TAAbs) in sera as diagnostic biomarkers for pancreatic cancer (PC). METHODS: Bioinformatics-based data mining and the customized proteome microarray based on cancer driver genes were used to identify the potential TAAs. Enzyme-linked immunosorbent assay (ELISA) was adopted to assess the expression levels of the corresponding autoantibodies in 457 serum samples, followed by a diagnostic model was then constructed using machine learning. RESULTS: Eleven candidate TAAs (EDNRA, OLR1, SEMA3C, AHNAK2, DHRS9, TMPRSS4, CCL20, SERPINB3, GPRC5A, TMC5 and MBOAT2) were identified through bioinformatics analysis and human protein chips, and further validated by ELISA. The titers of five TAAbs (anti-AHNAK2, anti-CCL20, anti-DHRS9, anti-OLR1, and anti-SERPINB3) that exhibited significant differences between PC and control subjects (P < 0.05), with AUC values ranging from 0.61 to 0.71. The random forest model developed using these five TAAbs exhibited AUCs of 0.83 (48.36 % sensitivity, 90.16 % specificity) and 0.76 (40.74 % sensitivity, 91.60 % specificity) for discriminating PC from healthy controls. Additionally, the model yielded AUCs of 0.86 (48.78 % sensitivity, 90.16 % specificity) and 0.80 (38.89 % sensitivity, 95.06 % specificity) for distinguishing early stage PC from controls in the training and test set, respectively. Notably, combining the random forest model with CA19-9 increased the positive rate to 88.97 %. CONCLUSION: Our findings indicated that the rondom froest model based on five autoantibodies might help identify preclinical and early-stage PC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAutoantibodiesEarly Detection of CancerHumansBiomarkers, TumorMaleFemaleMiddle AgedAntigens, NeoplasmAgedEnzyme-Linked Immunosorbent AssayComputational BiologyAdultProtein Array Analysis

Stichwörter der Autor:innen

BioinformaticsDiagnostic modelPancreatic cancerProteome microarrayTumor-associated antigens

Substanzen

AutoantibodiesBiomarkers, TumorAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
  • College of Public Health, Zhengzhou University, Zhengzhou, 450001, Henan Province, China; National Key Laboratory of Metabolism Disorder and Esophageal Cancer Prevention &Treatment, China; Henan Key Laboratory of Tumor…
  • Prenatal Diagnosis Center, The Third Affiliated Hospital of Zhengzhou University/Maternal and Child Health Hospital of Henan Province, Zhengzhou, 450052, China.
  • Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
  • College of Public Health, Zhengzhou University, Zhengzhou, 450001, Henan Province, China.
  • Zhengzhou Foreign Language School - New Fengyang Campus, Zhengzhou, 450001, Henan Province, China.

Förderung

  • Zhengzhou University

Zitieren

APA

Sun, L., Liu, Y., Yang, Q., Zhu, J., Li, T., Jiang, D., Lu, Y., Liu, L., Wang, Y., Zhang, X., Wang, Z., Ma, H., Shi, J., Wang, K., Wang, P., Song, C., Wang, K., & Ye, H. (2026). Serum autoantibody signatures enable non-invasive early detection of pancreatic cancer. Pancreatology. https://doi.org/10.1016/j.pan.2025.11.017

Vancouver

Sun L, Liu Y, Yang Q, Zhu J, Li T, Jiang D, et al. Serum autoantibody signatures enable non-invasive early detection of pancreatic cancer. Pancreatology. 2026. doi:10.1016/j.pan.2025.11.017

BibTeX
@article{Sun2026,
  author = {Sun, Li and Liu, Yuqi and Yang, Qian and Zhu, Jicun and Li, Tiandong and Jiang, Donglin and Lu, Yin and Liu, Ling and Wang, Yue and Zhang, Xiaodan and Wang, Zihan and Ma, Hanke and Shi, Jianxiang and Wang, Keyan and Wang, Peng and Song, Chunhua and Wang, Kaijuan and Ye, Hua},
  title = {Serum autoantibody signatures enable non-invasive early detection of pancreatic cancer},
  journal = {Pancreatology},
  year = {2026},
  doi = {10.1016/j.pan.2025.11.017}
}
Kostenlos starten →